Archive: Company News
Company News: Cardior Pharmaceuticals´ Lead Compound Demonstrates Improvement of Heart Function in Chronic Heart Failure Model
— Safety and efficacy of CDR132L established in an in vivo model of chronic post-MI heart failure
— Study by international research team published in European Heart Journal
— Broad treatment potential for chronic heart failure
Cardior Pharmaceuticals GmbH, a clinical-stage biotech company, focused on the development of noncoding RNA (ncRNA) therapeutics for patients with cardiovascular diseases, today announced a publication in the European Heart Journal (doi:10.1093/eurheartj/ehaa791) demonstrating that repeated treatment with its lead compound CDR132L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure. Read more…
Company News: Heraeus PALACADEMY® offers new online training courses for orthopaedic infection management and prevention
– New live webinar
– New Science Cast series
Heraeus PALACADEMY®, the educational platform of Heraeus Medical, features new online events on infection management in orthopaedics and traumatology with a focus on the prevention and management of periprosthetic joint infections and the relevance of local antibiotics.
Webinar as Live TV Event (submitted for CME credits) Read more…
Company News: Agena Bioscience Launches High-Throughput, Low-Cost SARS-CoV-2 Detection Panel in Europe with CE-IVD Marking
Agena Bioscience, a global provider of low cost and high-throughput molecular testing solutions, today announced that it has obtained CE-IVD marking for its SARS-CoV-2 Panel, an in vitro diagnostic test for the qualitative detection of the SARS-CoV-2 coronavirus that causes COVID-19.
Company News: T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy
T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced they have signed an agreement to provide technology transfer and cGMP clinical manufacturing of T-knife’s T1367 T-cell receptor (TCR) program.